Surgery Incisional Infections - Pipeline Insight, 2024

Surgery Incisional Infections - Pipeline Insight, 2024

DelveInsight’s, “Surgery Incisional Infections - Pipeline Insight, 2024” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Surgery Incisional Infections pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Surgery Incisional Infections: Understanding

Surgery Incisional Infections: Overview

Surgical site infections (SSIs) are a significant complication following surgical procedures, leading to increased morbidity, prolonged hospital stays, and higher healthcare costs. These infections occur at the incision site and can range from superficial skin infections to deep tissue or organ-space involvement. SSIs are caused by various pathogens, including bacteria and, less commonly, fungi, and can be influenced by patient-related risk factors such as obesity, diabetes, and immunosuppression, as well as surgical factors like the duration of the procedure and the use of prophylactic antibiotics.

The pathophysiology of surgery incisional infections involves a complex interplay of factors, including the primed and pretriggered host immune-inflammatory response to the invading pathogen, genetic predisposition, and the location, load, and virulence of the microbe. Surgical procedures evoke the innate immune system, triggering a systemic inflammatory response syndrome (SIRS) within hours of the injury. This acute nonspecific response is beneficial but paradoxically associated with reduced resistance to infection. The dysregulation of the immune-inflammatory response to the invasion of pathogens postoperatively is exacerbated by primed inflammation, which is influenced by factors such as age, underlying illnesses, type of invasive procedure, prolonged duration of surgical manipulation, ischemia and reperfusion, and transfusion. Innate immune receptors, such as Toll-like receptors (TLRs), contribute to detecting both pathogen-associated molecular patterns and endogenous damage-associated molecular patterns, further amplifying inflammatory responses to infection.

Surgery incisional infections symptoms include increasing pain, swelling, redness, and heat at the incision site, often accompanied by fever, chills, and a pus-like discharge. Superficial incisional SSIs may produce pus from the immediate wound site, while deep incisional SSIs can cause the wound site to reopen or become harder due to the inflammatory response. Organ or space SSIs can cause a discharge of pus from a surgical drain, which may be mixed with blood and have a foul odor. Additionally, patients may experience delayed healing, tenderness, warmth, or swelling at the incision site, which can be indicative of an SSI.

The treatment and management of surgery incisional infections, also known as surgical site infections (SSIs), involves a multifaceted approach aimed at controlling the infection, promoting wound healing, and preventing further complications. The initial step is to identify the causative pathogen through wound cultures and determine the extent of the infection. Superficial SSIs may be managed with local wound care, including dressing changes and topical antimicrobial agents. Deep incisional or organ/space SSIs often require surgical intervention, such as wound exploration and debridement, to remove necrotic tissue and foreign material. Antimicrobial therapy, guided by culture results, is typically administered systemically or topically, depending on the severity of the infection. Open wound management techniques, such as wound packing and negative pressure wound therapy, may be employed to facilitate healing. In cases of severe infection or poor wound healing, additional surgical procedures, such as skin grafting or flap reconstruction, may be necessary.

""Surgery Incisional Infections - Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Surgery Incisional Infections pipeline landscape is provided which includes the disease overview and Surgery Incisional Infections treatment guidelines. The assessment part of the report embraces, in depth Surgery Incisional Infections commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Surgery Incisional Infections collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Surgery Incisional Infections R&D. The therapies under development are focused on novel approaches to treat/improve Surgery Incisional Infections.

Surgery Incisional Infections Emerging Drugs Chapters

This segment of the Surgery Incisional Infections report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II/III, II, I, preclinical and discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Surgery Incisional Infections Emerging Drugs

D-PLEX: POLYPID

PolyPid's lead product candidate, D-PLEX, is a novel product candidate designed to provide local prolonged anti-bacterial activity directly at the surgical site to prevent SSIs. Following the administration of D-PLEX into the surgical site, the PLEX technology enables a prolonged and constant release of the broad-spectrum antibiotic doxycycline, resulting in high local concentration of the drug for a period of up to four weeks for the prevention of SSIs, with additional potential to treat antibiotic-resistant bacteria at the surgical site. The drug is currently being evaluated under Phase III clinical trial for the treatment of patients with Surgery Incisional Infections.

Further product details are provided in the report……..

Surgery Incisional Infections: Therapeutic Assessment

This segment of the report provides insights about the different Surgery Incisional Infections drugs segregated based on following parameters that define the scope of the report, such as:

MajorPlayers in Surgery Incisional Infections

There are approx. 3+ key companies which are developing the therapies for Surgery Incisional Infections. The companies which have their Surgery Incisional Infections drug candidates in the most advanced stage, i.e. Phase III include, POLYPID.

Phases

DelveInsight’s report covers around 3+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Surgery Incisional Infections pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intravenous

Subcutaneous

Oral

Intramuscular

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal antibody

Small molecule

Peptide

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Surgery Incisional Infections: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Surgery Incisional Infections therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Surgery Incisional Infections drugs.

Surgery Incisional Infections Report Insights

Surgery Incisional Infections Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Surgery Incisional Infections Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Surgery Incisional Infections drugs?

How many Surgery Incisional Infections drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Surgery Incisional Infections?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Surgery Incisional Infections therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Surgery Incisional Infections and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

POLYPID

MB Pharma

Key Products

D-PLEX

DUOFAG